What are the common sodium‑glucose co‑transporter 2 (SGLT2) inhibitors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Common SGLT-2 Inhibitors

The five commercially available SGLT-2 inhibitors are: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin 1, 2.

Available Agents

These medications, also known as the "gliflozin class," work by inhibiting the SGLT-2 cotransporter in the proximal renal tubules, thereby reducing glucose and sodium reabsorption and promoting urinary glucose excretion 1.

The Five SGLT-2 Inhibitors:

  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • Ertugliflozin
  • Sotagliflozin

All five agents are FDA-approved and share similar mechanisms of action, though they differ in their specific pharmacokinetic properties and approved indications 2, 3.

Current Clinical Applications

These agents have evolved far beyond simple glucose-lowering medications. Current guidelines now recommend SGLT-2 inhibitors as foundational therapy across multiple conditions 4, 5:

Primary Indications:

  • Chronic kidney disease (with or without diabetes) when eGFR ≥20 mL/min/1.73 m² 4, 5
  • Heart failure (HFrEF, HFmrEF, and HFpEF) regardless of diabetes status 5
  • Type 2 diabetes with high cardiovascular risk or established atherosclerotic cardiovascular disease 5
  • Cardiovascular-kidney-metabolic syndrome as part of integrated management 5

The 2024 BMJ guidelines represent a paradigm shift, recommending SGLT-2 inhibitors broadly for adults with CKD irrespective of diabetes status, moving beyond the previous restriction to only diabetic patients 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.